Bermúdez-Silva Francisco J, Suárez Pérez Juan, Nadal Angel, Rodríguez de Fonseca Fernando
Laboratorio de Medicina Regenerativa, Fundación IMABIS, Hospital Carlos Haya, Avda. Carlos Haya, Pabellón de Gobierno, sótano, 29010, Málaga, Spain.
Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):87-102. doi: 10.1016/j.beem.2008.10.012.
The endogenous cannabinoid system participates in the regulation of energy homeostasis, and this fact led to the identification of a new group of therapeutic agents for complicated obesity and diabetes. Cannabinoid receptor antagonists are now realities in clinical practice. The use of such antagonists for reducing body weight gain, lowering cholesterol and improving glucose homeostasis is based on the ability of the endocannabinoids to coordinately regulate energy homeostasis by interacting with central and peripheral targets, including adipose tissue, muscle, liver and endocrine pancreas. In this review we will analyse the presence of this system in the main cell types of the islets of Langerhans, as well as the physiological relevance of the endocannabinoids and parent acylethanolamides in hormone secretion and glucose homeostasis. We will also analyse the impact that these findings may have in clinical practice and the potential outcome of new therapeutic strategies for modulating glucose homeostasis and insulin/glucagon secretion.
内源性大麻素系统参与能量稳态的调节，这一事实促使人们发现了用于治疗复杂肥胖症和糖尿病的新型治疗药物。大麻素受体拮抗剂现已应用于临床实践。此类拮抗剂用于减轻体重增加、降低胆固醇和改善葡萄糖稳态，其依据是内源性大麻素能够通过与包括脂肪组织、肌肉、肝脏和内分泌胰腺在内的中枢和外周靶点相互作用，协同调节能量稳态。在本综述中，我们将分析该系统在胰岛主要细胞类型中的存在情况，以及内源性大麻素和母体酰基乙醇胺在激素分泌和葡萄糖稳态中的生理相关性。我们还将分析这些发现可能对临床实践产生的影响，以及调节葡萄糖稳态和胰岛素/胰高血糖素分泌的新治疗策略的潜在结果。
